Preimplantation Genetic Diagnosis (PGD) for Gender Selection
As you make the choice whether you want Preimplantation Genetic Diagnosis (PGD) testing done on your embryos, a factor to consider is the option for gender selection. Gender selection allows for family balancing, which is an option chosen by many patients in the Dallas/Fort Worth area.
During PGD, gender chromosomes are identified, making it possible to select embryos for implantation based on their classification as “male” or “female.”
Fluorescence In Situ Hybridization (FISH)
One of many methods of PGD is Fluorescence In Situ Hybridization (FISH), which screens 8-12 pairs of chromosomes once the embryonic stage has been reached. The goal of this screening is to reveal missing or surplus chromosomes, called Aneuploidy.
Potential limitations of FISH as a PGD tool is that it does not screen the full range of 23 pairs of chromosomes. Therefore, accuracy is a challenge.
Comparative Genomic Hybridization (CGH)
Center for Reproductive Endocrinology (previously SIRM-Dallas) worked through the years to refine a new method of PGD. Comparative Genomic Hybridization (CGH) is a method that is capable of screening all 23 pairs of chromosomes, thus greatly increasing reliability of the results compared to FISH. CGH is available at Center for Reproductive Endocrinology (previously SIRM-Dallas).
In addition to allowing for gender selection, this method accomplishes the main goals of genetic testing with high accuracy. CGH significantly increases the chances of live births by allowing for more comprehensive screening of embryos.